← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Accel Diagnostics, Llc
Houston, TX
$4,967,161
Total funding
9
Grants
Funding over time
peak $963.6K · FY2012–24$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,967,161 · 9
By mechanism
R44$2,643,679 · 2
R43$1,383,503 · 5
N44$727,427 · 1
N01$212,552 · 1
Investigators at Accel Diagnostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$963,581
R44 · FY2022 · AI
SBIR Topic 097, Phase II - Early Detection and Monitoring of Cardiac Injury Due to Cardiotoxicity$727,427
N44 · FY2019 · HL
A disposable assay for the monitoring of heart failure in the home setting.$611,965
R44 · FY2017 · HL
A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$398,753
R44 · FY2024 · AI
Blood Filtration System for the Treatment of Severe Malaria Patients$355,563
R43 · FY2012 · HL
A disposable assay for the monitoring of heart failure in the home setting.$331,659
R44 · FY2018 · HL
A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$240,405
R44 · FY2021 · AI
A disposable assay for the monitoring of heart failure in the home setting$225,133
R43 · FY2015 · HL
A rapid blood test to aid the triage of patients affected by head injuries.$223,966
R43 · FY2020 · NS
A Rapid Non-Invasive Device for Monitoring Preeclampsia in High Risk Pregnancy$215,450
R43 · FY2019 · HD
SBIR Topic 97 - Minimally Invasive Test for Chemotherapy-induced Cardiotoxicity - Phase I$212,552
N01 · FY2016 · HL
Blood Filtration System for the Treatment of Severe Malaria Patients$168,846
R43 · FY2013 · HL
A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood$145,499
R43 · FY2016 · AI
A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$97,316
R44 · FY2023 · AI
I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood.$49,046
R43 · FY2017 · AI